TCRX Stock Analysis: Buy, Sell, or Hold?
TCRX - TScan Therapeutics, Inc. Common Stock
$1.07
0.09 (9.17%)
▲
5d:
+21.47%
30d:
+5.94%
90d:
+5.94%
BUY
MODERATE Confidence
Analysis Updated: Jul 1, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When TCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TCRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TCRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TCRX is currently trading at $1.07, which is considered extended relative to its 30-day fair value range of $0.90 to $1.04.
Technical Outlook: Technically, TCRX is showing sideways momentum. Immediate support is located at $0.94, while resistance sits at $1.12. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: TCRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+460.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TCRX is showing sideways momentum. Immediate support is located at $0.94, while resistance sits at $1.12. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: TCRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.00 (+460.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.90 -
$1.04
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.2%)
- BULLISH: Trading 460.7% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$0.90 -
$1.04
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.94
Resistance Level
$1.13
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.21
Wall Street Target
$6.00
(+460.7%)
Revenue Growth (YoY)
-54.8%
Share & Embed Analysis
Last updated: July 01, 2026 6:22 PM ET
Data refreshes hourly during market hours. Next update: 7:22 PM
Data refreshes hourly during market hours. Next update: 7:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 64 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 56 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 53 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 60 HOLD |
